Skip to main content
Michael Glickman on Muck Rack

Michael Glickman

Westbury
As seen in: Nature, Wiley Online Library, PNAS, BioRxiv, Cell Press, Cell Reports, Crain's New York Business, American Society for Microbiology (ASM)
Join us on Sunday, June 22 at 11:00 a.m. for good food, family fun and old fashioned hospitality...Fun for the whole family!

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Molecular mechanisms underlying p62-dependent secretion of the Alzheimer-associated ubiquitin variant, UBB+1

|
By Ajay Wagh, Michael Glickman
| BioRxiv
Abstract UBB+1, a ubiquitin variant protein resulting from a frameshift in the ubiquitin-B gene, is a pathological hallmark of Alzheimer disease (AD). At the cellular level, UBB+1 disrupts the ubiquitin-proteasome system while inducing autophagy. Notably, UBB+1 itself is secreted via autophagosome-like vesicles. Here, we demonstrate that UBB+1 can be removed from the cell by degradative and secretory autophagy.
Open in Who Shared Issue with article?

Ubiquitin C‐Terminal Hydrolase L1 (UCHL1), Beyond Hydrolysis

|
By Michael Glickman, Anwar Bdarneh, Inbal Maniv
| Wiley Online Library Verified
AD Alzheimer's disease AMC 7-amino-4-methylcoumarin DUB deubiquitinating enzyme IF immunofluorescence PD Parkinson's disease SUMO small ubiquitin-like modifier UCH ubiquitin C-terminal hydrolase UCHL1 ubiquitin C-terminal hydrolase L1 UPS ubiquitin-proteasome system 1 Introduction Ubiquitin C-terminal hydrolase L1 (UCHL1) is an extensively studied enzyme, primarily due to its abundant levels in the brain [1].
Open in Who Shared Issue with article?

Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity

|
By Andrew W Daman, Anthony C. Antonelli, Gil Redelman-Sidi, Lucinda Paddock, Mythili Ketavarapu, Jin Gyu Cheong, Anna Benjamin, Song Jiang, Michael J Bale, Oleg Loutochin, Victor A. McPherson, Maziar Divangahi, Rachel E. Niec, Dana Pe’er, Eugene J. Pietzak, Steven Josefowicz, Michael Glickman, Shireen Khayat, Leonardo F. Jurado, Dughan Ahimovic, Victoria R. Lawless
| Cell Press Verified
Keywords bladder cancer BCG immunotherapy tumor immunity trained immunity innate immune memory hematopoiesis epigenetics Get full text access Log in, subscribe or purchase for full access. References 1. Dobosz, P. ∙ Dzieciątkowski, T. The intriguing history of cancer immunotherapy Front. Immunol. 2019; 10:2965 2. Heney, N.M. Natural history of superficial bladder cancer. Prognostic features and long-term disease course Urol. Clin. North Am. 1992; 19:429-433 3. Böhle, A. ∙ Jocham, D.
Open in Who Shared Issue with article?
See all 24 articles